Telix Pharmaceuticals (NASDAQ:TLX) Shares Climb 0.5% – Should You Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price rose 0.5% on Monday. The stock traded as high as $10.85 and last traded at $10.74. 249,389 shares changed hands during trading, a decline of 43% from the average session volume of 434,302 shares. The stock had previously closed at $10.69.

Key Stories Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue increased 19% year over year. Telix reported continued commercial growth for the quarter ended September 30, 2026, supporting the company’s expanding radiopharmaceutical business. Telix Pharmaceuticals Q3 Revenue Rises 19%
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook and highlighted ongoing progress across pipeline programs. Maintaining the forecast indicates that recent operating performance remains broadly on track. Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline Programs
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $22 price target, signaling that the analyst sees substantial potential upside based on Telix’s commercial execution and pipeline.
• Neutral Sentiment: Telix also updated its third-quarter and full-year 2026 earnings guidance, while reports characterized the full-year outlook as reaffirmed rather than materially increased. Investors may therefore be looking for stronger upgrades to accelerate the stock’s recovery.
• Negative Sentiment: The market reaction has been weak despite the positive revenue result. Coverage describing the shares as “crashing” indicates possible profit-taking, disappointment that guidance was not raised, or concern that growth expectations were already reflected in the valuation. Telix shares crashing 8% today: What happened?

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Friday, September 25th. Finally, Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Price Performance

The stock has a 50 day moving average of $11.49 and a 200 day moving average of $10.78. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares in the last quarter. XY Capital Ltd bought a new stake in Telix Pharmaceuticals during the first quarter worth $120,000. WoodTrust Financial Corp bought a new stake in Telix Pharmaceuticals during the third quarter worth $186,000. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at $1,731,000. Finally, Private Advisor Group LLC boosted its holdings in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.